UCB SA: 1 director

A director at UCB SA bought 200 shares at 216.000EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...

ING Benelux Favourites/Weekly performance and valuation update

The ING Benelux Favourites list comprises ASM, Basic-Fit, DSM-Firmenich, Lotus Bakeries, SBM Offshore, Vopak, Wolters Kluwer and Xior.

Morning Notes : ABN NA, CRBN NA, ENX FP, GBLB BB, PROX BB, UCB BB

: ABN NA, CRBN NA, ENX FP, GBLB BB, PROX BB, UCB BB

UCB/Bimzelx, the best-in-disease drug in HS/BUY

We reiterate our BUY rating on UCB and increase our target price from €238 to €257 on higher expected peak sales for Bimzelx, after Moonlake's weaker-than-expected P3 results in Hidradenitis Suppurativa, as well as the successful approval of UCB's Kygevi in TK2d. We continue to view UCB's risk/reward balance as favourable, with the group pipeline accounting for only 6% of Enterprise Value. Despite some concerns regarding Bimzelx's growth trajectory over the past month, compounded by data collect...

Galapagos 9M25 conference call feedback

Galapagos reported 9M25 results and hosted a conference call to discuss its results. We provide the key takeaways from the call in this note.

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 11/06/2025

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 06/11/2025

Galapagos : Refocusing impacting margins

Morning Notes : AED BB, COFB BB, GLPG NA, JEN BB, SOLB BB, VGP BB, SHU...

: AED BB, COFB BB, GLPG NA, JEN BB, SOLB BB, VGP BB, SHUR BB, CTPNV NA, IMCD NA, SYENS BB

Galapagos : Un recentrage qui impacte la marge

Galapagos 9M25 results hold no surprises, new outlook following cell T...

Galapagos reported 9M25 results with a cash position of € 3,050m (YE24: € 3,317.8m) and an updated outlook, where it expects to end FY25 with € 2,975- € 3,025m in cash, and to incur costs of € 250-325m related to the winddown of the cell therapy business. Looking ahead, the company will focus its strategy on building a new pipeline through BD, and more information on BD strategy will be provided during this afternoon's conference call. € 37 TP and ACCUMULATE maintained.

Benelux Morning Notes

Ahold Delhaize: Strong beat driven by one-offs Alfen: Bull bear fight continues bpost: 3Q25 results in line with INGF but miss vs consensus, FY25 outlook fine-tuned to top-end CM.com: Takeover offer from Bird Coca-Cola Europacific Partners: Refreshing D'Ieteren: Belron peer Driven Brands 3Q25 talks of lower Q4, choppiness in Collision and Direct Repair Exor: Ferrari reassures with strong 3Q25, improved guidance KPN: Strategy update reassures, largely in line, with solid cash returns expec...

Morning Notes : KIN BB, ONTEX BB, UCB BB, UMI BB, DEME BB

: KIN BB, ONTEX BB, UCB BB, UMI BB, DEME BB

UCB Secures FDA approval for Kygevvi in ultra-rare disease TK2d

UCB announced that Kygevvi (doxecitine and doxribtimine) has been granted approval by the US FDA in adults and paediatric patients living with thymidine kinase 2 deficiency (TK2d), with an age of symptom onset on or before 12 years. The approval comes in line with the company's guidance of a decision before YE25, making it the first and only approved treatment in this setting. Note that TK2d is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64 p...

Umicore FIRST LOOK: Silicon-anodes JV with HS Hyosung Advance Material...

After more than a decade of R&D efforts on developing silicon carbon composite anode materials for EV batteries, Umicore now believes its technology is ready for industrialization & commercialization and has announced its intention to create a JV with HS Hyosung Advanced Materials. Umicore will retain a minority stake in the JV, which will allow the group to limit expenditure for the roll-out of its anode technology. This approach is very much in sync with the approach taken for the cathode acti...

ASH abstracts: Autolus, Galapagos, MaaT

The abstracts for presentations at the American Society of Haematology conference (ASH, 6-9 December) became available yesterday during the day (HERE). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (new data for Aucatzyl in paediatric ALL, real world data in adult ALL, amongst others), Galapagos (additional CAR-T data in r/r MCL and r/r DLBCL) and MaaT (longer follow up from ...

Benelux Morning Notes

Azelis: Appointment of Boris Cambon-Lalanne as group CFO. Belgian Telecoms: Price increase on most of the non-commercialised products and Scarlet trio. D'Ieteren: Belgian October car registrations down 7%, VW down 20%. Kendrion: Results preview; launching share buyback programme. Kinepolis: Acquires US movie theatre chain Emagine Entertainment for US$105m. Kinepolis: October box office in US/Canada and France attendance drop again. Ontex: Branded activity now fully divested. Philip...